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Data sharing: not as simple as it seems
Neil Pearce1,2* and Allan H Smith3
Abstract
In recent years there has been a major change on the part of funders, particularly in North America, so that data
sharing is now considered to be the norm rather than the exception. We believe that data sharing is a good idea.
However, we also believe that it is inappropriate to prescribe exactly when or how researchers should preserve and
share data, since these issues are highly specific to each study, the nature of the data collected, who is requesting
it, and what they intend to do with it. The level of ethical concern will vary according to the nature of the
information, and the way in which it is collected - analyses of anonymised hospital admission records may carry a
quite different ethical burden than analyses of potentially identifiable health information collected directly from the
study participants. It is striking that most discussions about data sharing focus almost exclusively on issues of
ownership (by the researchers or the funders) and efficiency (on the part of the funders). There is usually little
discussion of the ethical issues involved in data sharing, and its implications for the study participants. Obtaining
prior informed consent from the participants does not solve this problem, unless the informed consent process
makes it completely clear what is being proposed, in which case most study participants would not agree. Thus,
the undoubted benefits of data sharing does not remove the obligations and responsibilities that the original
investigators hold for the people they invited to participate in the study.
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Background
In recent years there has been a major change on the
part of funders, particularly in North America, so that
data sharing is now considered to be the norm rather
than the exception. Data sharing is clearly, in general, a
good idea. However, it is not as simple as it seems. The
devil is in the detail, and the detail is highly specific to
each study, and each potential data recipient. In this
paper, we will therefore discuss some of the concerns
and caveats which should be taken into account in any
data sharing policy, or any individual decision about
data sharing.
More than twenty years ago, one of us (NP) was
involved in a series of studies that identified a beta ago-
nist asthma drug (fenoterol) as the cause of an epidemic
of asthma deaths in New Zealand [1]. The accuracy of
the data was disputed by other researchers, so prior to
publication we organised several reviews, conducted
blind, where they sat down with us and reviewed the
general practitioner questionnaires and the hospital
records (which were the basis for the drug prescribing
data); this found that the classification of the data had
been accurate [2]. However, following publication, the
study findings were strongly disputed by the pharmaceu-
tical company involved [2], and by an ‘expert panel’
which was assembled by the company [3]. The company
requested the raw data for the studies, using the New
Zealand Official Information Act, which applies to
universities.
We checked with the regulations of the New Zealand
Medical Research Council, our main funder, and these
stated that data could be shared with other ‘bona fide
researchers’, but the decision was to be left up to the
researchers who had originally collected the data - it
was they who should decide who were ‘bona fide
researchers’ who the data could be shared with. Since
we did not consider the company, or its hired consul-
tants, to be ‘bona fide researchers’ - in fact, we felt they
had a vested interest in the issue, and had seriously mis-
represented the published findings of our studies [4-6] -
we were not inclined to give them a copy of the data.
Furthermore, we were concerned about confidentiality,
since New Zealand is a small place, and study partici-
pants could potentially be identified on the basis of
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demographic data, even if the data set was ‘anonymised’.
Also, we considered that it was inappropriate for the
company to be given the data without specifying in
advance what analyses it intended to conduct.
We offered the company a solution: it could specify in
advance what its planned analyses were, and someone
nominated by the company could then visit our research
group, and we would do the analyses with them, without
handing over a copy of the data. The company was
unwilling to accept this option, and persisted with its
claim for the data under the Official Information Act.
We therefore referred the matter to the Ethics Commit-
tees that had originally approved the study. All but one
of them ruled that the company should not be given the
data - the other Committee was unwilling to make a
ruling, but recommended that the Company should
apply directly to them, and they would consider the
request. We also referred the issue to the New Zealand
Ombudsman, who has jurisdiction over Official Infor-
mation Act requests. After reviewing the issue in detail
for several months, the Office of the Ombudsman ruled
that the data should not be given to the company, on
the grounds that it was impossible to protect confidenti-
ality, even if personal identifiers such as name and date-
of-birth were removed.
More recently, one of us (NP again) was involved in
another dispute about data sharing, from the other side.
He was involved in producing a report on the health
status of the population of the Pacific Island country of
Tonga, with funding from the World Health Organisa-
tion (WHO) [7]. Surveys had been conducted, by a
group of Australian researchers, in 2004, as part of the
WHO STEPwise approach to Surveillance (STEPS) pro-
ject, but few of the findings had been published, and the
researchers were apparently unwilling to make the data
available to the Tonga Ministry of Health. Our report
noted that:
“The Tonga STEPS study... has collected very useful
data on [non-communicable diseases] NCDs and
their risk factors. Participation in similar such sur-
veys is important to ensure the continuation of accu-
rate determination of disease prevalence in Tonga.
However, it is a concern that little of the STEPS
data has been published (four years after it was col-
lected), and of the materials published little is avail-
able to the Ministry of Health. The raw data set has
not been made available to the Tongan Ministry of
Health, or to the authors of this report. It is essential
that in future, a copy of such data is made available
to the Tongan Ministry of Health. Otherwise, such
surveys will be of little benefit to the health of
Tongans.”
In this instance, we were attempting, on behalf of the
Tonga Ministry of Health, to obtain access to a data set
collected (with cooperation and assistance from the
Ministry of Health) by a group of university-based
researchers. A couple of years ago, one of us (NP) was
involved in such a dispute from the other side, where
his university-based research group was denied access to
a data set collected by the New Zealand Ministry of
Health. Our group had produced a series of monitoring
reports, funded by the Ministry of Health, on the New
Zealand National Cervical Screening Programme
(NCSP) [8-11]. The programme was established in 1991,
and ever since had been dogged by adverse publicity
[12]. Our own reports had highlighted ethnic differences
in screening access and uptake; our contract was termi-
nated after four years. Independently of that, we were
conducting a programme of research into demographic
differences in cervical cancer survival, with a particular
focus on ethnic differences [13-15]. We managed to
obtain access to a NCSP data set for a small number of
cervical cancer cases for one particular set of analyses
[14], but our request for further access to the Registry
data, in order to investigate ethnic differences in screen-
ing, and how these had changed over time, was denied,
even though the study was funded by the Health
Research Council (HRC) of New Zealand, had received
ethical approval, and had also received approval from
the National Kaitiaki Group (a Maori Committee which
exercises guardianship over the Maori data in the Regis-
try), and the Pacific Women’s Advisory Group. Confi-
dentiality was one of the key reasons given for refusing
access to the data, despite all of the necessary approvals
having been obtained; one can only speculate whether
the possibility of further adverse publicity about the
shortcomings of the screening programme may have
also played a role.
These three incidents, over two decades, illustrate the
hazards and benefits of data-sharing. In the two decades
since the fenoterol studies were published, there has
been a major change on the part of funders, particularly
in North America, so that data sharing is now consid-
ered to be the norm rather than the exception. In fact,
it would be a brave researcher nowadays who declared
themselves to be against data sharing - they would gen-
erally be regarded as having something to hide, and
would be unlikely to obtain further funding (just in case
any of our potential funders are reading this, let us
assure them that we are not against data sharing under
appropriate conditions!). On the other hand, there has
been increased concern about confidentiality and access
(by researchers) to patient records [16]. So access (by
other researchers) to data collected by researchers has
perhaps become more easy, whereas access (by
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researchers) to data collected by governments has in
some cases become more difficult.
Options for data sharing
The usual options for data sharing were outlined in a
recent Request For Information from the National Insti-
tutes of Health (NIH) regarding strategies to encourage
broad data sharing in environmental health sciences
research [17]. The options include: (i) a study investiga-
tor responding ad hoc to individual requests for data;
(ii) establishing informal collaborative networks among
investigators with common interests to conduct focused
analyses (e.g. data pooling); and (iii) regular deposits of
study data in a data enclave or externally-managed pub-
lic archive.
The options for data sharing were also recently
reviewed by Reiter and Kinney [18]. They noted that
simply stripping a data set of unique identifiers such as
names, addresses, and identification numbers may not
suffice. For example, Sweeney showed that 97% of
records in voter registration lists for Cambridge, MA,
could be uniquely identified using birth date and 9-digit
zip code. In fact similar methods have been used on
census data in New Zealand to create cohorts that can
be followed over time, and linked with cancer and death
registration data [19,20].
Reiter and Kinney classified data sharing into
restricted-access strategies, and restricted data strategies.
Restricted-access involves sharing unaltered confiden-
tial data with external researchers while preserving confi-
dentiality. This can be achieved by: (i) providing a copy
of the data under a license agreement to researchers with
legitimate research questions and (possibly) destroyed at
project completion; or (ii) researchers may be required to
carry out their analyses in a physically and electronically
secure facility controlled by the data steward, and may be
required to first submit a research proposal.
Restricted-data strategies involve unfettered access to
data that have been modified before release. The key
issue is how much information should be deleted or
transformed to ensure data protection without destroy-
ing the usefulness of the data [18]. Risks can be reduced
by altering data, e.g. by coarsening, data swapping, noise
addition, or synthetic data [18].
It is noteworthy that none of these proposed data-
sharing strategies involves simply making the data set
available to anyone who requests it. Data-sharing is
viewed as a matter of negotiation rather than compul-
sion. Furthermore, most approaches rely on a ‘data
steward’ (usually the researchers who collected the data)
who decides who should have access to the data (i.e.
who is a ‘legitimate researcher’ or who has a ‘legitimate
research question’) and in what form it should be made
available.
Funders
Funders naturally like data sharing because it appears to
make better use of the resources that they have allo-
cated for research. The NIH Statement on Sharing
Research Data states that “NIH reaffirms its support for
the concept of data sharing. We believe that data shar-
ing is essential for expedited translation of research
results into knowledge, products, and procedures to
improve human health. The NIH endorses the sharing
of final research data to serve these and other important
scientific goals” [21]. More recently input has been
sought by the National Institute for Environmental
Health Sciences (NIEHS) on “strategies to encourage
broader data sharing among researchers in the field of
environmental health science who are conducting clini-
cal or epidemiologic studies.”[17] The United Kingdom-
based Wellcome Trust website states that “we aim to
ensure that the data generated by the research we sup-
port is managed and shared in a way that maximises the
benefit to the public.” Similarly the United Kingdom
Medical Research Council (MRC) website states that:
Our policy builds on the central principles of the
Organisation for Economic Co-operation and Devel-
opment (OECD) in its report “Promoting Access to
Public Research Data for Scientific, Economic and
Social Development”. These are that publicly-funded
research data are a public good, produced in the
public interest, and that they should be openly avail-
able to the maximum extent possible... Our data
sharing and preservation policy applies to all MRC-
funded research. It does not prescribe when or how
researchers should preserve and share data, but
requires them to make clear provision for doing so
when planning and executing their research.
Most other similar funding bodies have now adopted
similar policies, i.e. they do not prescribe how data
should be shared, but they require that applicants for
funding have a plan for doing so.
Journals
Some journals (but few epidemiology journals to date),
are now also requiring data-sharing. Journal policies
were recently reviewed by Alsheikh-Ali et al [22]. They
found that of the 50 original research journals with the
highest impact factor, 44 (88%) had a statement about
data sharing; there was a wide variety of journal require-
ments, ranging from requiring the sharing of all primary
data to just including a statement in the published
manuscript stating that data can be available on request.
Of 500 assessed papers, 149 (30%) were not subject to
any data availability policy; of the remaining 351 papers,
208 (59%) did not fully adhere to the data availability
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instructions, most commonly (73%) by not publicly
depositing microarray data. It is notable, however, that
the majority of papers considered were molecular
research, which would carry much less (or often zero)
issues of confidentiality compared with epidemiological/
observational studies, which were underrepresented in
the sample [22]. This is an important issue for epide-
miologists, since journal policies may evolve with a
focus on molecular research, where mandatory data
sharing does not raise the same ethical issues.
Recently, the publishers of this journal (BMC) issued a
draft position statement on open data (http://blogs.
openaccesscentral.com/blogs/bmcblog/resource/openda-
tastatementdraft.pdf) which was strongly in favour of
data sharing, but stated that:
The decision to mandate data deposition as a condi-
tion of publication is another decision best made by
the scientific community concerned rather than a
single journal or publisher... We will, therefore, sup-
port data publication when it is mandated, but will
also enable, encourage and recognize data sharing
and publication on a voluntary basis for scientists
wishing to show leadership in their field.
A corollary of this approach is that it would be useful
to have a statement in published manuscripts, similar to
the Competing Interests Statement, that sets out the
degree of availability or openness of the data.
The investigators
Researchers, understandably, may have more mixed feel-
ings about data sharing. This usually stems from two
main concerns.
Firstly, there is the question of ‘ownership’. It is under-
standable that researchers may feel unhappy if they work
for several years to develop a research proposal, get the
funding, get the ethical approval, hire staff, collect the
data, clean the data, and produce the first publication, to
then have the data quickly “shared” with investigators
who have done none of this work. This is not a trivial
issue, since a single study may produce a whole series of
publications, but data may be required to be shared as
soon as the first publications in the series have appeared.
For example, the NIH statement of sharing research data
states that “NIH recognizes that the investigators who
collect the data have a legitimate interest in benefiting
from their investment of time and effort. We have there-
fore revised our definition of the timely release and shar-
ing to be no later than the acceptance for publication of
the main findings from the final data set”[21]. The word-
ing used does not define “main findings” and presumably
allows for the fact that the main findings from a study
may be published in several papers over some years.
These issues were at the core of a recent dispute in
which data on sperm counts in Denmark were published
without the permission of the researchers who had col-
lected it [23]. The researchers in question were required
to supply the data as part of internal reports to the Dan-
ish National Board of Health, who then posted a graph
online, which was then incorporated into a paper pub-
lished in Epidemiology [24]. An accompanying editorial
[25] noted that “the presentation of a few raw data on a
Web site - or in a commentary - is hardly the preferred
way to advance science. But neither is it acceptable for
valuable data to be held in storage. The publication of
these data in Epidemiology does not foreclose the oppor-
tunity for researchers to prepare a full and careful analy-
sis of their data.”
It is clearly not in the public interest to have data col-
lected for research projects funded by public money to
be lying unpublished for many years. However, it is also
clearly not in the public interest for researchers to feel
that it is not worth collecting the data in the first place,
and that an easier path to publication, and scientific
glory, is simply to regularly request access to data that
colleagues have collected. Both extremes are not in the
interests of science, or public health. A balanced
approach is required in which data is made available, to
genuine researchers with a genuine research question,
once the initial investigators have had an adequate time
to publish their main findings.
The second issue that is usually of major concern to
the researchers who collected the data is usually the
possibility of the data being obtained by hostile agencies
with vested interests in the outcome of the study. Such
disputes have perhaps become more frequent in recent
years [26]. The usual approach is for the company con-
cerned to hire consultants to criticise the research pub-
licly, either when it appears in print, or even prior to
publication [27]. In recent years, these efforts have been
further developed and refined with the use of websites
and publicity that stigmatizes unwelcome research find-
ings as “junk science” [28]. In some instances these
activities have gone as far as efforts to block publication
[2]. Recent examples include attempts to influence stu-
dies on the toxicity of benzene [29] and diesel particu-
late matter [30], the various industry efforts over many
years to influence the conduct and interpretation of
research into the health effects of dioxin [31], the indus-
try campaign to undermine an Occupational Safety and
Health Administration (OSHA) chromium (VI) standard
[32] and corporate infiltration of a panel convened to
set standards for chromium (VI) in California [33].
More recently, epidemiology in general, and occupa-
tional epidemiology in particular, has been criticised for
a inherent tendency to produce false positive findings
[34], a view which has been disputed by other
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epidemiologists including one of the authors (NP) [35].
It is in this context that, at least from some quarters,
demands for data-sharing have arisen, e.g. with respect
to industry attempts to dispute the findings of studies of
health effects of air pollution in the United States [36].
As one of us (NP) commented recently, “for every
independent epidemiologist studying the side effects of
medicines and the hazardous effects of industrial chemi-
cals, there are several other epidemiologists hired by
industry to attack the research and to debunk it as ‘junk
science’.”[37] Compulsory data-sharing with such ‘hired
guns’, particularly when the primary researchers have
not had the full chance to publish their findings, creates
even more disincentives to collect primary data in the
first place. This is bad for everyone, including the ‘hired
guns’ who will have no contracts if independent
researchers are no longer collecting primary data which
they can subsequently critique.
The study participants
So who is missing from this debate? The study partici-
pants! It is striking that most discussions about data
sharing focus almost exclusively on issues of ownership
(by the researchers or the funders) and efficiency (on
the part of the funders). There is usually little discussion
of the ethical issues involved in data sharing, and its
implications for the study participants, apart from the
requirement that (usually) participants are not able to
be identified from the data set that is shared.
Obviously the issues involved differ according to the
way that the data was collected, and the information
that was collected. For example, sharing of routine
death certificates, or even cancer registrations, carries
quite different ethical considerations to that of sharing
data that was collected by an individual researcher (or
group) for a specific study, in which informed consent
was obtained. The response to this dilemma from many
funding agencies is simply that the informed consent
process should include consent to the data being shared.
However, our experience is that most study participants
would not fully understand what was involved in such a
request, and if they did they would probably say “no”.
We therefore consider that it is unethical for us to
request study participants to sign an ‘informed consent’
that we would not sign ourselves.
It’s one thing to consent that “the researchers may
carry out further analyses of the data including analyses
of additional health outcomes and/or analyses which
involve colleagues from other researcher groups”. It’s
completely another issue to agree that ‘anyone, even
companies with vested interests, or members of the gen-
eral public, will be able to obtain a copy of the data
from this study, with the names and dates of birth
removed’. Requiring such ‘genuinely informed consent’
would see most epidemiological research grind to a halt,
which is in the interests of neither researchers, funders,
the general public, or science itself.
These issues are particularly acute in community-
based studies, e.g. of occupational or environmental
exposures and their health effects. Usually, the Principal
Investigator and the Co-investigators will be named on
the consent form, which may also explicitly list which
other researchers will have access to the data. Prior to
ethical approval, and funding, being obtained, the
researchers may hold a series of meetings with commu-
nity leaders and potential participants - this is particu-
larly the case in countries like New Zealand where
research may involve indigenous communities [38].
Usually, the communities concerned will only give con-
sent for a study to proceed once they trust the research-
ers, and are confident that the data will be used
carefully, and will not be shared with other researchers
unless the main research group retains control over, and
responsibility for, the way that the data is used and
reported. Researchers may also be required to go
through many other ‘hoops’ to gain ethical approval,
including assurances about how the data will be stored,
how confidentiality will be maintained, how the findings
will be reported back to study participants, and who will
be consulted before the findings are published.
The problem with compulsory data sharing is that it
completely bypasses these necessary checks and bal-
ances. In the most extreme case, other researchers may
simply be able to ‘take’ data that has been collected
under very stringent conditions, and use it any way that
they wish, without having to go through any form of
ethical approval, and without specifying their research
protocol in advance. In this extreme situation, data shar-
ing raises very significant ethical concerns, which go way
beyond the needs of funders, researchers, or the scienti-
fic community.
And how should informed consent be obtained for
such data sharing? If the consent is “informed” it needs
to be explained. Here is an example of what might be
needed:
This study is being directed by Professor xxx of the
University of yyy. The study is being conducted
because preliminary findings suggest that arsenic
concentrations in your drinking water may be harm-
ful to your health. More information is needed to
confirm this, and it is for this reason we are inviting
you to participate in our study. If we do find scienti-
fically valid evidence of increased health risks, it is
possible that the arsenic drinking water standard
may be reconsidered and lowered by the Environ-
mental Protection Agency (EPA). However, the
National Institutes of Health (NIH) which funds our
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work requires that we share the data with others,
even if they refuse to collaborate with us. This
includes mining companies, who believe the current
drinking water standard is already too low. Runoff
water from the mining properties has to meet drink-
ing water standards, and the mining companies do
not wish to pay for the costs of further cleanup.
They have already hired consultants who have been
opposed to our previous work. Your name and all
personal identifiers will be removed from any data
given to them, but you may see publications from
this study by the mining companies or their consul-
tants who already claim that there are no increased
health risks from arsenic in your water. Sorry about
that, but please sign this form anyway”.
Discussion
So what is the solution? We believe that data sharing is
a good idea, and the onus should be on researchers to
share their data with other researchers once the main
findings have been published. However, we also believe
that it is inappropriate to prescribe exactly when or how
researchers should preserve and share data, since these
issues are highly specific to each study, the nature of the
data collected, who is requesting it, and what they
intend to do with it. The level of ethical concern will
vary according to the nature of the information, and the
way in which it is collected - analyses of anonymised
hospital admission records may carry a quite different
ethical burden than analyses of potentially identifiable
health information collected directly from the study
participants.
Furthermore, we believe that data sharing works best
when it leads to collaborative work. Most epidemiologi-
cal studies involve complex data and valid analysis and
interpretation of the data would be much more likely if
those responsible for the study design and data collec-
tion are involved. In short, to enhance the quality of any
further analysis, the first goal should be to involve the
original investigators in the work. This is not accom-
plished by forcing investigators to place their data on
accessible web-sites.
Thus, the prime responsibility for the ethical use of
the data must surely lie with the researchers who col-
lected it. This is particularly appropriate when the data
was collected from individual study participants with
prior consultation with the relevant communities. In
this situation it is clearly unethical for the Principal
Investigator to permit any potentially inappropriate use
of data from their study. One way for ethically accepta-
ble data sharing to occur is for the original researchers
to: (i) only send data for reanalysis (or invite the other
researchers to undertake a joint re-analysis) after having
approved the planned work; (ii) be given the opportunity
to be co-authors of any resulting publications; and (iii) if
collaboration breaks down, then having the right to have
a letter-to-the editor or accompanying commentary
published at the same time, and in the same journal, as
the reanalysis.
It is now widely recognised (e.g. in privacy legislation
in many countries), that the ultimate responsibility for
any particular data set (e.g. health records, cancer regis-
trations) lies with the person(s) or agency that collected
the data, and they have the responsibility to make the
decisions as to who the data can or should be shared
with, and for what purposes. Researchers may have an
obligation to share data, under appropriate circum-
stances, but they also have the right and obligation to
decide not to do so if the proposed uses of the data are
inappropriate or unclear. Of course, in some instances
researchers may inappropriately choose not to share
their data, and colleagues and funding agencies may
then respond appropriately, in terms of scepticism about
the validity of the published work and/or lack of oppor-
tunities for further funding. So this approach is not
without its difficulties. However, the alternative, i.e.
compulsory data-sharing without any restriction on who
can obtain a copy, has even greater difficulties, and
much greater ethical and scientific concerns.
Conclusions
In conclusion, we consider that any blanket requirement
that datasets be made public after completion of a study
is unethical. Obtaining prior informed consent from the
participants does not solve this problem, unless the
informed consent process makes it completely clear
what is being proposed, in which case most study parti-
cipants would not agree. Thus, we agree that “data from
epidemiologic studies should be available for impartial
reanalysis and reinterpretation regardless of whether the
study was funded by public monies or by groups with
particular interests or ideologies” [39] and that “the ori-
ginal authors have a responsibility to cooperate with,
and facilitate, impartial and competent reanalysis and
reinterpretation of their data” [39]. However, this does
not remove the obligations and responsibilities that the
original investigators hold for the people they invited to
participate in the study.
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